Elanco Animal Health Inc (ELAN) Stock Price & Analysis
Elanco Animal Health Inc (ELAN) rose 3.46% to USD 24.5 as of June 10, 2026 at 00:50 UTC, according to Nexqual real-time market data.
ELAN last closed at USD 23.68; the session ranged USD 23.95–24.67 on volume of 5,123,136 shares. Market capitalization is $12.24B, with a 52-week range of USD 13.16–27.72 (NYQ). Source: Nexqual, June 10, 2026 at 00:50 UTC.
Key Statistics (as of June 10, 2026 at 00:50 UTC)
| Price | USD 24.5 |
|---|---|
| Change | ▲ 3.46% (up) |
| Previous Close | USD 23.68 |
| Open | USD 24.04 |
| Day Range | USD 23.95 – 24.67 |
| 52-Week Range | USD 13.16 – 27.72 |
| Volume | 5,123,136 shares |
| Market Cap | $12.24B |
| Exchange | NYQ |
Technical Analysis (ELAN)
Nexqual's technical model rates ELAN "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:50 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.27 (neutral) |
| vs SMA50 | Above (USD 22.89) |
| MACD | 0.46 (positive) |
Analyst Ratings (ELAN)
Wall Street analysts rate ELAN "Strong Buy" based on 14 analysts, with a mean price target of USD 29.79 (range USD 23–32), per Nexqual as of June 10, 2026 at 00:50 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 14 |
| Mean Target | USD 29.79 |
| High Target | USD 32 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 15 / 2 / 0 |
Earnings (ELAN)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.27 |
| Revenue Estimate | $1.31B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.4 vs est 0.34 ▲ beat |
| 2025-12-31 | USD 0.13 vs est 0.12 ▲ beat |
| 2025-09-30 | USD 0.19 vs est 0.13 ▲ beat |
| 2025-06-30 | USD 0.26 vs est 0.2 ▲ beat |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financials & Fundamentals (ELAN)
| Total Revenue | $4.89B |
|---|---|
| Revenue Growth (YoY) | +14.90% |
| Gross Margin | +55.06% |
| Operating Margin | +12.33% |
| Profit Margin | -4.95% |
| ROE | -3.77% |
| Debt / Equity | 66.15 |
| Current Ratio | 2.16 |
| Total Cash | $428.00M |
| Total Debt | $4.30B |
| Free Cash Flow | $692.12M |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financial Health Score (ELAN)
Nexqual rates Elanco Animal Health Inc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:50 UTC.
| Growth | Solid — Revenue +6% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 12% |
| Balance Sheet | Strong — $428M cash vs $4.30B debt |
| Cash Flow | Solid — FCF $692M, 15% margin |
| Efficiency | Critical — ROE -4%, ROA 1.5% |
Ownership (ELAN)
| Insider Ownership | +1.22% |
|---|---|
| Institutional Ownership | +111.32% |
| Shares Outstanding | 499.45M |
| Float | 494.84M |
| Short % of Float | +10.55% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Leadership (ELAN)
Elanco Animal Health Inc is led by Jeffrey N. Simmons (age 58), President, CEO & Director, per Nexqual as of June 10, 2026 at 00:50 UTC.
| President, CEO & Director | Jeffrey N. Simmons (age 58) |
|---|---|
| Executive VP & CFO | Robert M. VanHimbergen (age 49) |
| Executive VP & President of Elanco International | Ramiro Martin Cabral (age 53) |
| Executive Vice President of Research, Development & Regulatory Affairs | Ellen de Brabander (age 62) |
| Executive Vice President of Center of Strategic Growth | Timothy J. Bettington (age 51) |
Major Backers & Investors (ELAN)
Notable institutional backers of Elanco Animal Health Inc include Dodge & Cox Inc., FMR, LLC, Primecap Management Company, according to Nexqual as of June 10, 2026 at 00:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Dodge & Cox Inc. | 22.86% |
| FMR, LLC | 10.2% |
| Primecap Management Company | 9.18% |
| T. Rowe Price | 8.74% |
| Winslow Capital Management, LLC | 2.73% |
| Fidelity | 1.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 22.99% |
| BlackRock | 12.9% |
| Dimensional Fund Advisors | 4.91% |
| State Street | 3.07% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
From Elanco Animal Health Inc's Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.
- It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry.
- In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry.
- Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AVTR | Avantor, Inc. | USD 9.91 | ▲ 8.19% |
| ZTS | Zoetis Inc. | USD 82.2 | ▲ 3.47% |
| BHC | Bausch Health Companies Inc. | USD 5.17 | ▼ 3.72% |
| BHVN | Biohaven Ltd. | USD 11.09 | ▲ 2.69% |
| EQH | Equitable Holdings, Inc. | USD 41.93 | ▲ 2.77% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:50 UTC. This page is informational and not investment advice.